Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
Toss A, Tenedini E, Piombino C, Venturelli M, Marchi I, Gasparini E, Barbieri E, Razzaboni E, Domati F, Caggia F, Grandi G, Combi F, Tazzioli G, Dominici M, Tagliafico E, Cortesi L. Toss A, et al. Among authors: barbieri e. Genes (Basel). 2021 Apr 21;12(5):616. doi: 10.3390/genes12050616. Genes (Basel). 2021. PMID: 33919281 Free PMC article.
Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
Guarneri V, Pecchi A, Piacentini F, Barbieri E, Dieci MV, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli P. Guarneri V, et al. Among authors: barbieri e. Ann Surg Oncol. 2011 Aug;18(8):2150-7. doi: 10.1245/s10434-011-1590-x. Epub 2011 Feb 8. Ann Surg Oncol. 2011. PMID: 21301969
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
Dieci MV, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, Guarneri V. Dieci MV, et al. Among authors: barbieri e. J Clin Pathol. 2012 Jun;65(6):503-6. doi: 10.1136/jclinpath-2011-200643. Epub 2012 Mar 3. J Clin Pathol. 2012. PMID: 22389512
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
Omarini C, Bettelli S, Caprera C, Manfredini S, Barbolini M, Moscetti L, Isca C, Toss A, Barbieri E, Cortesi L, Kaleci S, Maiorana A, Tazzioli G, Cascinu S, Piacentini F. Omarini C, et al. Among authors: barbieri e. J Cancer Res Clin Oncol. 2019 Apr;145(4):821-828. doi: 10.1007/s00432-018-02833-8. Epub 2019 Jan 2. J Cancer Res Clin Oncol. 2019. PMID: 30603906
Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies.
Toss A, Venturelli M, Molinaro E, Pipitone S, Barbieri E, Marchi I, Tenedini E, Artuso L, Castellano S, Marino M, Tagliafico E, Razzaboni E, De Matteis E, Cascinu S, Cortesi L. Toss A, et al. Among authors: barbieri e. Cancers (Basel). 2019 Feb 7;11(2):193. doi: 10.3390/cancers11020193. Cancers (Basel). 2019. PMID: 30736435 Free PMC article.
Breast ultrasound in high-risk women.
Cortesi L, Barbieri E, Toss A. Cortesi L, et al. Among authors: barbieri e. Oncotarget. 2019 Feb 22;10(16):1552-1553. doi: 10.18632/oncotarget.26713. eCollection 2019 Feb 22. Oncotarget. 2019. PMID: 30899424 Free PMC article. No abstract available.
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S, Keupp K, Kiechle M, Kölbl A, Krieger S, Kruse TA, K… See abstract for full author list ➔ Parsons MT, et al. Among authors: barbieri e. Hum Mutat. 2019 Sep;40(9):1557-1578. doi: 10.1002/humu.23818. Hum Mutat. 2019. PMID: 31131967 Free PMC article.
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials.
Omarini C, Piacentini F, Sperduti I, Barbolini M, Isca C, Toss A, Cortesi L, Barbieri E, Dominici M, Moscetti L. Omarini C, et al. Among authors: barbieri e. BMC Cancer. 2020 May 13;20(1):418. doi: 10.1186/s12885-020-06933-y. BMC Cancer. 2020. PMID: 32404154 Free PMC article.
719 results